Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ: EDIT )

1.540 -0.070 (-4.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths. 
Via Investor's Business Daily
Where Editas Medicine Stands With Analysts
Via Benzinga
Looking for Stock Bargains With Room to Run? Try This.
Investing tips from Bill Mann, The Motley Fool's director of small-cap research. 
Via The Motley Fool
Editas Medicine to Participate in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
Boot Barn To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Unveiling 5 Analyst Insights On Editas Medicine
Via Benzinga
The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts
Via Benzinga
Editas Medicine Announces Second Quarter 2024 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
From Editas Medicine, Inc.
Via GlobeNewswire
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
Explore gene-editing stocks with potential to become multibaggers as the industry advances in treating genetic disorders. 
Via InvestorPlace
3 Profitable CRISPR Stocks Earning Analysts’ Praise
Revolutionary gene-editing technologies provide promise for investors seeking the most profitable CRISPR stocks today and in the future. 
Via InvestorPlace
The 3 Best Gene Editing Stocks to Buy in July 2024
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. 
Via InvestorPlace
The Latest Analyst Ratings For Editas Medicine
Via Benzinga
Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich
Gene editing is a game-changer, creating substantial opportunities for some of the leading gene editing stocks. 
Via InvestorPlace
3 Gene Editing Stocks That Could Make Your Grandchildren Rich
Explore gene-editing stocks with long-term growth potential, offering innovative solutions to previously untreatable conditions. 
Via InvestorPlace
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
From Editas Medicine, Inc.
Via GlobeNewswire
Overlooked and Undervalued: 3 Stocks With Jaw-Dropping Upside Potential
Invest in these undervalued stocks poised for long-term growth as Wall Street shifts focus to broader market gains. 
Via InvestorPlace
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
The company has great potential if and when it enters the commercial stage. 
Via The Motley Fool
EDIT Stock Earnings: Editas Medicine Misses EPS, Misses Revenue for Q1 2024
EDIT stock results show that Editas Medicine missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Editas Medicine Announces First Quarter 2024 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases 
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.
The company now has a chance to get its lead program out the door a bit sooner. 
Via The Motley Fool
1 Beaten-Down Stock With 55% Upside, According to Wall Street
The biotech has bounced back some in the past year. 
Via The Motley Fool
Why Editas Medicine Stock Soared as Much as 42% Higher This Week
The clinical-stage genome editing company dropped a couple of important announcements for shareholders. 
Via The Motley Fool
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.